Publications by authors named "Maria Dimova"
Article Synopsis
- Ankylosing Spondylitis (AS) is a chronic inflammatory arthritis linked to higher cardiovascular risks, primarily due to accelerated atherosclerosis, although some studies show mixed results regarding this association.
- Endothelial dysfunction, common in AS patients, amplifies the effects of inflammation and traditional cardiovascular risk factors, potentially speeding up artery damage before other vascular issues arise.
- Investigations suggest key factors like adhesion molecules can predict cardiovascular events, and treatments such as angiotensin receptor blockers and statins might lower cardiovascular risks in AS patients, highlighting the need for further studies.
Background: Rheumatoid arthritis (RA) increases the risk of cardiovascular disease (CVD), with inflammation playing a key role. Biologic and targeted synthetic drugs used to treat RA can induce systemic immunomodulation and may have pleiotropic effects on vascular function, making it crucial to investigate their impact on CVD risk in RA patients.
Methods: A systematic review of the literature was conducted to investigate the impact of biologic and targeted synthetic treatments approved for RA on various cardiovascular markers, including endothelial function, arterial stiffness, and subclinical atherosclerosis.
Background: Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-dose combination of indacaterol (IND), a long-acting β2-adrenergic agonist (LABA), and glycopyrronium (GLY), a long-acting muscarinic antagonist (LAMA) for use as maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Objective: To determine the economic benefits of IND/GLY compared with the free combination of indacaterol and glycopyrronium (IND + GLY), and with the fixed-dose combination of salmeterol/fluticasone (SFC), in a moderate-to-severe COPD population with low-exacerbation risk. The model-based analysis extrapolated results up to lifetime time horizon and calculated costs per quality-adjusted life year.
Direct costs of unintended pregnancy in the Russian federation.
Appl Health Econ Health Policy
February 2015
Background: In 2010, almost every third pregnancy in Russia was terminated, indicating that unintended pregnancy (UP) is a public health problem.
Objective: The aim of this study was to estimate the direct cost of UP to the healthcare system in Russia and the proportion attributable to using unreliable contraception.
Methods: A cost model was built, adopting a generic payer perspective with a 1-year time horizon.